Hypermetabolism of fat in V1a vasopressin receptor knockout mice.
[Arg8]Vasopressin (AVP) has an antilipolytic action on adipocytes, but little is known about the mechanisms involved. Here, we examined the involvement of the V1a receptor in the antilipolytic effect of AVP using V1a receptor-deficient (V1aR-/-) mice. The levels of blood glycerol were increased in V1aR-/- mice. The levels of ketone bodies, such as acetoacetic acid and 3-hydroxybutyric acid, the products of the lipid metabolism, were increased in V1aR-/- mice under a fasting condition. Triacylglyceride and free fatty acid levels in blood were decreased in V1aR-/- mice. Furthermore, measurements with tandem mass spectrometry determined that carnitine and acylcarnitines in serum, the products of beta-oxidation, were increased in V1aR-/- mice. Most acylcarnitines were increased in V1aR-/- mice, especially in the case of 2-carbon (C2), C10:1, C10, C14:1, C16, C18:1, and hydroxy-18:1-carbon (OH-C18:1)-acylcarnitines under feeding rather than under fasting conditions. The analysis of tissue C2-acylcarnitine level showed that beta-oxidation was promoted in muscle under the feeding condition and in liver under the fasting condition. An in vitro assay using brown adipocytes showed that the cells of V1aR-/- mice were more sensitive to isoproterenol for lipolysis. These results suggest that the lipid metabolism is enhanced in V1aR-/- mice. The cAMP level was enhanced in V1aR-/- mice in response to isoproterenol. The phosphorylation of Akt by insulin stimulation was reduced in V1aR-/- mice. These results suggest that insulin signaling is suppressed in V1aR-/- mice. In addition, the total bile acid, taurine, and cholesterol levels in blood were increased, and an enlargement of the cholecyst was observed in V1aR-/- mice. These results indicated that the production of bile acid was enhanced by the increased level of cholesterol and taurine. Therefore, these results indicated that AVP could modulate the lipid metabolism by the antilipolytic action and the synthesis of bile acid via the V1a receptor.
Hiroyama
Masami
M
Department of Pharmacology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan.
Aoyagi
Toshinori
T
Fujiwara
Yoko
Y
Birumachi
Junichi
J
Shigematsu
Yosuke
Y
Kiwaki
Kohji
K
Tasaki
Ryuji
R
Endo
Fumio
F
Tanoue
Akito
A
D020155:3-Hydroxybutyric Acid / Q000378:metabolism; D000090:Acetoacetates / Q000378:metabolism; D017667:Adipocytes / Q000378:metabolism*; D000273:Adipose Tissue / Q000378:metabolism*; D000818:Animals; D002784:Cholesterol / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D005990:Glycerol / Q000097:blood; D007657:Ketone Bodies / Q000378:metabolism; D008055:Lipids / Q000737:chemistry; D051379:Mice; D018345:Mice, Knockout; D017483:Receptors, Vasopressin / Q000235:genetics* / Q000502:physiology*; D014280:Triglycerides / Q000378:metabolism; D014667:Vasopressins / Q000378:metabolism*
D000090:Acetoacetates; D005227:Fatty Acids; D007657:Ketone Bodies; D008055:Lipids; D017483:Receptors, Vasopressin; D014280:Triglycerides; D014667:Vasopressins; C016635:acetoacetic acid; D002784:Cholesterol; D005990:Glycerol; D020155:3-Hydroxybutyric Acid